64Cu-DOTA-ECLIi

N/A

Report date: 2025/11/21 17:16:16
NME

Base Information

Drug Name64Cu-DOTA-ECLIi
Drug Alias NameN/A
ClassificationDiagnostic agent (In vivo)Small moleculesRadiation-emitting products > Radioactive diagnostic agent +[5] 
Mechanisms of ActionC-C chemokine receptor type 2 modulators
TargetsC-C chemokine receptor type 2
Therapy Area/IndicationsCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesWashington University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of Medicine
Inactive CompaniesN/A
Active IndicationsCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A